Outcome and follow-up
The patient first received eculizumab in 2019, which significantly
improved and stabilized his condition as assessed by several pertinent
physician- and patient-reported outcome measures of MG symptoms and
severity and QoL (Besinger, quantitative MG [QMG], MG activities of
daily living [MG-ADL], and MG-QoL [15-item questionnaire]
[MG-QoL15] scores) (Figures 1 and 2 ). Following a short
discontinuation of eculizumab treatment in 2020 due to cost-associated
challenges, the patient experienced MG regression, including a
myasthenic crisis (Figures 1 and 2 ). However, the patient’s
condition quickly improved (within 12 days) upon reinitiating
eculizumab. In 2022, the patient switched from eculizumab to ravulizumab
without any complications and is currently still being treated with
bi-weekly ravulizumab and reduced steroid intake (Figures 1 and
2 ).